6X3P image
Entry Detail
PDB ID:
6X3P
Keywords:
TRANSFERASE
Title:
Co-structure of BTK kinase domain with L-005298385 inhibitor
Biological Source:
Source Organism:
Homo sapiens
Host Organism:
Spodoptera frugiperda
PDB Version:
Deposition Date:
2020-05-21
Release Date:
2020-07-22
Method Details:
Experimental Method:
X-RAY DIFFRACTION
Resolution:
1.34 Å
R-Value Free:
0.21
R-Value Work:
0.20
R-Value Observed:
0.20
Space Group:
P 21 21 2
6X3P validation report
Macromolecular Entities
Protein Blast
Polymer Type:polypeptide(L)
Description:Tyrosine-protein kinase BTK
Chain IDs:A
Chain Length:271
Number of Molecules:1
Biological Source:Homo sapiens
UniProt ID:Q06187 Pfam ID:PF07714 EC:2.7.10.2
Ligand Molecules
BTB
EDO
UM4
Primary Citation
Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes.
Bioorg.Med.Chem.Lett. 30 127390 127390 (2020)
PMID: 32738973 DOI: 10.1016/j.bmcl.2020.127390

Abstact

Bruton's tyrosine kinase (BTK) is a Tec family kinase with a well-defined role in the B cell receptor (BCR) pathway. It has become an attractive kinase target for selective B cell inhibition, and for the treatment of B cell related diseases. Many BTK inhibitors have been discovered for the treatment of cancer and rheumatoid arthritis, including a series of BTK inhibitors based on 8-amino-imidazo[1,5-a]pyrazine we recently reported. The X-ray crystal structures of BTK with inhibitors were also published, which provided great help for the SAR design. Here we report our SAR work introducing ring constraints for the 3-position piperidine amides on the BTK inhibitors based on 8-amino-imidazo[1,5-a]pyrazine. This modification improved the potency in BTK inhibitions, as well as the PK profile and the off-target selectivity. The dose-dependent efficacy of two BTK inhibitors was observed in the rat collagen induced arthritis (CIA) model.

Legend

Protein

Chemical

Disease

Primary Citation of related structures
6X3P